BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 4038653)

  • 1. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II diaziquone chemotherapy in brain tumors.
    Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
    Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
    [No Abstract]   [Full Text] [Related]  

  • 5. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory lymphoma.
    McLaughlin P; Cabanillas F; Bedikian AY; Bodey GP
    Cancer Treat Rep; 1983 May; 67(5):507-8. PubMed ID: 6850666
    [No Abstract]   [Full Text] [Related]  

  • 7. Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial.
    Budman DR; Forastiere A; Perloff M; Perry M; Aisner J; Weinberg V; Wood W
    Cancer Treat Rep; 1982 Oct; 66(10):1875-6. PubMed ID: 7127327
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II evaluation of diaziquone in recurrent head and neck cancer.
    Kish JA; Ensley J; Al-Sarraf M
    Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
    Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
    Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of diaziquone in malignant mesothelioma.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Nichols WC
    Cancer Treat Rep; 1986 Mar; 70(3):429. PubMed ID: 3955559
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Sutton GP; Homesley HD; Park R
    Cancer Treat Rep; 1986 Feb; 70(2):309-10. PubMed ID: 3948196
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
    Chamberlain MC; Prados MD; Silver P; Levin VA
    J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study.
    Shildt R; Stephens RL; Subramanian VP; Baker LH; Fletcher WS; O'Bryan RM; McCracken JD
    Cancer Treat Rep; 1985 Jun; 69(6):709-10. PubMed ID: 4016775
    [No Abstract]   [Full Text] [Related]  

  • 15. Response variability of human brain tumors to AZQ in tissue culture.
    Kornblith PL; Rosa L; Bona JD; Edwards JA; Matuzic N; Hirschfeld A; Hawkins C
    J Neurooncol; 1986; 4(1):49-54. PubMed ID: 3746385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
    Frytak S; Eagan RT; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
    Creagan ET; Schutt AJ; Ahmann DL; Green SJ
    Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical evaluation of AZQ in metastatic breast cancer.
    Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
    Chan C; Bartolucci A; Brenner D; Presant C; Davila E; Carpenter J; Greco FA; Clamon G; Moore J
    Cancer Treat Rep; 1986 Mar; 70(3):427-8. PubMed ID: 3456834
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study.
    Zidar BL; Baker LH; Rivkin SE; Balcerzak SP; Stephens RL
    Cancer Treat Rep; 1985 Sep; 69(9):1035-6. PubMed ID: 4028037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.